Torrent Pharmaceuticals Limited — Important, 25-10-2024: Financial Result Updates

Torrent Pharmaceuticals reported a 9% revenue growth to Rs. 2,889 crores for Q2 FY25, with a net profit of Rs. 453 crores, up 17%. Operating EBITDA grew 14% to Rs. 939 crores, with a margin of 32.5%. Indian revenues increased by 13%, driven by strong performance in chronic therapies. Global markets also showed growth, with notable results in Brazil and Germany. The insulin segment experienced a temporary slowdown due to maintenance activities. Overall, underlying revenue growth was 10% for the quarter.